NEXT STEPS TO GETTING STARTED ON GATTEX

The Takeda Patient Support Program offers personalized assistance throughout your treatment journey

Now that you've decided to start treatment with GATTEX, completed the Start Form, and elected to enroll in the Takeda Patient Support Program, please refer to the checklist below to see what you can expect next.

Your Takeda Patient Support team includes your dedicated **Patient Support Manager (PSM)**. Upon enrollment, your PSM will call you to:

- Explain Takeda Patient Support services and obtain your consent
- Confirm the information on your Start Form, including insurance benefits and coverage

Your PSM welcome call may last around 30 minutes. **Please be sure to have your insurance information available.**

| Your PSM (Name, Phone) | |
|------------------------|--|
| | |

Your Takeda Patient Support team also includes your **Onboarding & Access Specialist (OAS)**. Your OAS will set up a meeting to help you get started with treatment and answer any questions related to:

- Insurance and financial assistance options
- GATTEX and potential side effects
- Next steps in your treatment journey

| Your OAS (Name, Phone) | |
|------------------------|--|
| | |

Once your insurance company approves your GATTEX prescription, it will be sent to you by a **specialty pharmacy** (a mail-order pharmacy that provides specialty medications)

 Your specialty pharmacy will reach out to confirm delivery and can also guide and support you in administering your treatment

A **Nurse Educator** (ie, GATTEX Injection Training Nurse) will come to your home and train you on how to administer GATTEX according to the Instructions for Use

- The Nurse Educator can meet with you up to 4 times to ensure that you know how to administer GATTEX
- Please contact your OAS or PSM for ongoing support

Note: Depending on your insurance, the timeline for starting GATTEX can vary. To avoid delays, **please be sure to answer calls** from your Takeda Patient Support team, specialty pharmacy, and Nurse Educator, which may come from unknown numbers.

Call Takeda Patient Support at 1-866-888-0660, Monday through Friday, 8:30 AM to 8:00 PM eastern time, or visit gattex.com/getting-started to learn more.

Please discuss any questions with your doctor.





Available for patients 1 year of age and older

Takeda Patient Support Start Form: Authorization for Services





FAX PAGE 1 OF THIS FORM TO: 1-855-359-3393 PHONE: 1-866-888-0660

| 1. PATIENT INFORMATION | | | | |
|--|---|--|--|--|
| Full Name | | Caregiver (First, Last) | | |
| DOB (MM/DD/YYYY) | Male Female | Relationship to Patient | Phone | |
| Last 4 Digits of SSN E | Email | | By providing the names of my other Care Team Members on this form (healthcare | |
| _ | | providers other than the GATTEX prescribing physician), I am authorizing any employees of the Companies to follow up with these Care Team Members to provide education and information about GATTEX. | | |
| City/State/ZIP | | | | |
| Primary Phone | Secondary Phone | | Phone | |
| Special Precautions (eg, allergies) | | _ Español es mi primer idioma | *Optional. | |
| I would like to opt in to marketing | ng communications. | | | |
| X | ease of my protected health information, as described or | n Page 2, Section 6 of this form. | - Date | |
| Takeda Patient Support Progran | n and Communications Enrollment e of my personal information for the purposes described | on Page 2, Section 7 of this form. | | |
| Patient signature/legal represent | ative signature (indicate relationship) | | Date | |
| 2. INSURANCE INFORMATION | | | | |
| REQUIRED: Include copies of both sid | es of the patient's medical and prescription insu | urance card(s) Check if the patient does | not have insurance | |
| <u> </u> | Insurance Phone | • | Insurance Phone | |
| | Group | | _ Group | |
| | | | | |
| DOB (MM/DD/YYYY) | Relationship to Patient | _ DOB(MM/DD/YYYY) | Relationship to Patient | |
| Pharmacy Plan | Policy ID # | Group # | | |
| Pharmacy Plan Phone | Rx Bin # | Rx PCN # | | |
| - | | | | |
| 3. PRESCRIBING PHYSICIAN INFORMA | | 4. PATIENT CLINICAL INFORMATION | | |
| | ATION Treatment Center | _ Diagnosis* | Etiology | |
| Full Name | | _ Diagnosis* New Start Short bowel syndrome (SBS) patient | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's | |
| Full NameAddress | Treatment Center | Diagnosis* New Start Short bowel syndrome (SBS) patient | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) | |
| Full NameAddressCity/State/ZIP | Treatment Center | Diagnosis* New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, | |
| Full NameAddressCity/State/ZIPPhone | Treatment Center | Diagnosis* New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, | |
| Full NameAddressCity/State/ZIPPhone | Treatment Center Fax Office Contact Name | Diagnosis* New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies. Date of Last | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) | |
| Full NameAddress | Treatment Center Fax Office Contact Name | Diagnosis* New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies. | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, | |
| Full Name | Treatment Center Fax Office Contact Name Office Contact Email | Diagnosis* New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies. Date of Last Intestinal Resection | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support | |
| Full Name | Treatment Center Fax Office Contact Name Office Contact Email glutide) FOR INJECTION e-specific prescription requirements such as steeck one box below) g kit is not recommended in patients weighing le | New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies. Date of Last Intestinal Resection ICD-10 Code ate-specific prescription form, e-prescribing, STEP 2: Choose # | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. | |
| Full Name | Treatment Center Fax Office Contact Name Office Contact Email glutide) FOR INJECTION e-specific prescription requirements such as steeck one box below) | New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies. Date of Last Intestinal Resection ICD-10 Code ate-specific prescription form, e-prescribing, STEP 2: Choose # | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. of 30-vial kits needed e than 3.8 mg/day, two 30-vial kits | |
| Full Name | Fax Office Contact Name Office Contact Email Office Contact Name Office Contact Name Office Contact Name Office Contact Name Office Contact Email | New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal Please do not check a box if neither applies. Date of Last Intestinal Resection ICD-10 Code ate-specific prescription form, e-prescribing, STEP 2: Choose # ses than 10 kg) pairment or end-stage 3 m²) If dose is mor | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. of 30-vial kits needed e than 3.8 mg/day, two 30-vial kits | |
| Full Name | Fax Office Contact Name Office Contact Email | New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal Please do not check a box if neither applies. Date of Last Intestinal Resection ICD-10 Code ate-specific prescription form, e-prescribing, STEP 2: Choose # Is than 10 kg) Dairment or end-stage 3 m²) If dose is mor are recomme | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. of 30-vial kits needed e than 3.8 mg/day, two 30-vial kits | |
| Full Name | FaxOffice Contact NameOffice Contact EmailOffice Contact EmailOffice Contact EmailOffice Contact Email | New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal Please do not check a box if neither applies. Date of Last Intestinal Resection ICD-10 Code ate-specific prescription form, e-prescribing, STEP 2: Choose # be sthan 10 kg) cairment or end-stage 3 m²) If dose is mor are recomme one (mg/day) One (1) 30-Vial Two (2) 30-Vial A maximum of 0.3 | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. et of 30-vial kits needed et han 3.8 mg/day, two 30-vial kits nded† | |
| Full Name | Treatment Center Office Contact Name Office Contact Email glutide) FOR INJECTION e-specific prescription requirements such as stated to the company of the | New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies. Date of Last Intestinal Resection ICD-10 Code ate-specific prescription form, e-prescribing, STEP 2: Choose # If dose is mor are recomme Two (2) 30-Vial Two (2) 30-Vial Two (2) 30-Vial Ta maximum of 0.3 teduglutide, can be served. | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. et of 30-vial kits needed et han 3.8 mg/day, two 30-vial kits nded† Kit/NDC # 68875-0102-01/Vial Size: 5 mg | |
| Full Name | Fax Office Contact Name Office Contact Email | New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal *Please do not check a box if neither applies. Date of Last Intestinal Resection ICD-10 Code ate-specific prescription form, e-prescribing, ses than 10 kg) pairment or end-stage 3 m²) If dose is mor are recomme one (mg/day) One (1) 30-Vial Two (2) 30-Vial A maximum of 0.3 teduglutide, can by | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. et of 30-vial kits needed et han 3.8 mg/day, two 30-vial kits nded† Kit/NDC # 68875-0102-01/Vial Size: 5 mg Ikits/NDC # 68875-0102-01/Vial Size: 5 mg Image: Mikits/NDC # 68875-0102-01/Via | |
| Full Name Address City/State/ZIP Phone Treatment Center Name Office Contact Phone National Provider ID 5. PRESCRIPTION FOR GATTEX (tedu The prescriber must comply with stat STEP 1: Calculate patient dosage (ch Dose: 0.05 mg/kg once daily (5 mg Reduce dose to 0.025 mg/kg once renal disease (estimated glomerul Complete both calculations patient weight (kg) STEP 3: Enter directions Administer By signing this form, I certify that therapy with GATTEX is mer representative, the necessary authorization to release, in acco for the purpose of seeking information related to coverage ar used for Patient. I understand that I am under no obligation to | Fax Office Contact Name Office Contact Email | New Start Short bowel syndrome (SBS) patient dependent on parenteral nutrition and/or IV fluids (parenteral support) Existing Patient GATTEX renewal Please do not check a box if neither applies. Date of Last Intestinal Resection ICD-10 Code ate-specific prescription form, e-prescribing, STEP 2: Choose # Step 1 dose is mor are recomme Two (2) 30-Vial Two (2) 30-Vial The Maximum of 0.3 teduglutide, can be subcutaneously, under the skin, once dail reviewed the current GATTEX Prescribing Information and will be supervisited for the patient information relating to GATTEX therapy to Takeda Pharm attent Support to transmit this prescription to a pharmacy within the GATT | Inflammatory Bowel Disease (IBD) (eg, chronic conditions such as Crohn's disease) Non-IBD (eg, acute events [vascular event, trauma, intestinal obstruction], congenital anomaly [gastroschisis, midgut volvulus]) Parenteral Support Provider/Pharmacy etc. et of 30-vial kits needed et han 3.8 mg/day, two 30-vial kits needed kit/NDC # 68875-0102-01/Vial Size: 5 mg Kit/NDC # 68875-0102-01/Vial Size: 5 mg Kits/NDC # 68875-0102-01/Vial Size: 5 m | |

Authorization for Takeda Patient Support

PLEASE READ THROUGH THE LANGUAGE ON THIS PAGE BEFORE SIGNING THE AUTHORIZATION AND CONSENT IN SECTION 1 OF THE START FORM.

6. PATIENT AUTHORIZATION TO SHARE PROTECTED HEALTH INFORMATION

I authorize any health plan, physician, health care professional, hospital, clinic, pharmacy provider or other health care provider (collectively, "Providers") to disclose my protected health information, including personal information relating to my medical condition, treatment, care management, and health insurance, as well as all information provided on this form and any prescription ("Information"), to Takeda Pharmaceutical Company Limited, its affiliates and their representatives, agents, and contractors (collectively, the "Company" or "Takeda") in connection with the Company's provision of products, supplies, or services. I understand the Company will provide this Information to a specialty pharmacy to fulfill the prescription. This Information may also be used for internal uses by the Company, including data analysis. Further, I understand that my physician, health insurance, and pharmacy providers may receive financial remuneration from the Companies for providing Protected Health Information, which may be used for marketing purposes.

Further, the Company may use this Information for Takeda Patient Support Services ("Services") (if I agree on page 1) such as verification of insurance benefits and drug coverage, prior authorization support, financial assistance with co-pays, patient assistance programs, alternate funding sources, other related programs, communication with me or my prescribing physician by mail, email, or telephone about my medical condition, treatment, care management, product information and health insurance.

I understand that once disclosed to the Company, my Personal Health Information disclosed under this Authorization may no longer be protected by federal privacy law, including HIPAA. I understand that I am entitled to a copy of this Authorization. I understand that I may cancel this Authorization at any time by sending written notice of revocation to Takeda Patient Support, 300 Shire Way, Lexington, MA 02421. I understand that such revocation will not apply to any information already used or disclosed through this Authorization. This Authorization will expire within five (5) years from today's date, unless a shorter period is provided for by state law.

I understand that I may refuse to sign this Authorization and that refusing to sign this Authorization will not change the way my physician, health insurance, and pharmacy providers treat me. I also understand that if I do not sign this Authorization, I will not be able to receive Services from Takeda.

7. TAKEDA PATIENT SUPPORT ENROLLMENT

By signing the Takeda Patient Support Program and Communication Enrollment section on page 1, section 1, I am electing to enroll in the Services and direct all disclosures of my Information in connection with such Services (which may include, but is not limited to, verification of insurance benefits and drug coverage, prior authorization support, financial assistance with co-pays, patient assistance programs, alternate funding sources, other related programs, communication with me or my prescribing physician by mail, email, or telephone about my medical condition, treatment, care management, product information and health insurance).

8. PATIENT CONSENT FOR MARKETING COMMUNICATIONS

By checking the box on page 1, section 1, I authorize the use of my Information for Takeda marketing activities and consent to receiving marketing and promotional communications from Takeda. I hereby give consent to Takeda, its affiliates, and their agents and representatives to send communications and information to me via the contact information I have provided on page 1. I understand that this consent will be in effect until I cancel such authorization.

Please click here for full **Prescribing Information**.



